Ovarian adenocarcinoma
MONDO:0002752An adenocarcinoma that arises from the ovary. It is the most common type of ovarian carcinoma. It includes the serous adenocarcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, and endometrioid adenocarcinoma.
Also known as: adenocarcinoma of ovary, adenocarcinoma of the ovary, ovarian adenocarcinoma, ovary adenocarcinoma
3064 clinical trials for this condition and its sub-types, 12 tagged with Ovarian adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ovarian adenocarcinoma
-
Ovarian serous adenocarcinoma 199 trials · 203 incl. sub-types
3 sub-types
-
Ovarian endometrioid adenocarcinoma 78 trials
1 sub-type
-
Ovarian clear cell adenocarcinoma 22 trials · 26 incl. sub-types
1 sub-type
-
Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types
1 sub-type
- Ovarian mucinous cystadenocarcinoma 4 trials
-
Ovarian cystadenocarcinoma 0 trials · 5 incl. sub-types
3 sub-types
- Ovarian clear cell cystadenocarcinoma 4 trials
- Ovarian mucinous cystadenocarcinoma 4 trials
- Ovarian serous cystadenocarcinoma 4 trials
-
Krukenberg carcinoma 1 trial
-
Rete ovarii adenocarcinoma 0 trials
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to stall ovarian Cancer's return
Disease control OngoingThis phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …
Phase 2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC